SCHEMBL1979233

SCHEMBL1979233

CC(C)(C)OC(=O)N1CC2CC(C1)N2C(=O)C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.49
CHRM2 P08172 1/20 0.45
CHRM1 P11229 1/20 0.45
CHRM3 P20309 1/20 0.45
RORC P51449 1/20 0.40
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PREP P48147 3/20 0.39
USP30 Q70CQ3 1/20 0.38
LIPE Q05469 1/20 0.38
HPGD P15428 1/20 0.38
EPHX2 P34913 1/20 0.38
KDM4E B2RXH2 1/20 0.37
RECQL P46063 1/20 0.36
EPHX1 P07099 1/20 0.36
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
NAMPT P43490 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25344924 0.89 CHRM2 (0.51) NR1H2CHRM2CHRM1CHRM3RORC
SCHEMBL31049077 0.88 USP2 (0.45) NR1H2CHRM2CHRM1CHRM3RORC
SCHEMBL27372641 0.83 NR1H2 (0.51) NR1H2CHRM2CHRM1CHRM3USP2
SCHEMBL30194962 0.83 NR1H2 (0.51) NR1H2CHRM2CHRM1CHRM3USP2
SCHEMBL31049143 0.81 NR1H2 (0.43) NR1H2CHRM2CHRM1CHRM3RORC
SCHEMBL30276651 0.80 NR1H2 (0.55) NR1H2RORCUSP2SMN1; SMN2USP30
SCHEMBL30276459 0.80 NR1H2 (0.55) NR1H2RORCUSP2SMN1; SMN2USP30
SCHEMBL21739097 0.80 NR1H2 (0.54) NR1H2CHRM2CHRM1CHRM3RORC
SCHEMBL929357 0.79 CHRM2 (0.55) NR1H2CHRM2CHRM1CHRM3USP2
SCHEMBL18702051 0.79 CHRM2 (0.54) NR1H2CHRM2CHRM1CHRM3USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315880-A1 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS TARGACEPT INC (US) 2014-10-23 US disclosed
US-8802694-B2 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands TARGACEPT, INC. (US) 2014-08-12 US disclosed
US-20120309737-A1 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands TARGACEPT, INC. (US) 2012-12-06 US disclosed
EP-2509982-A1 3,6-DIAZABICYCLO[3.1.1]HEPTANES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS Targacept, Inc. (US) 2012-10-17 EP disclosed
WO-2011071758-A1 3,6-DIAZABICYCLO[3.1.1]HEPTANES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315880-A1 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA3, CHRNA6 NR1H2 348/4885CHRM2 23/4885CHRM1 22/4885
US-20120309737-A1 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands CHRNA3, CHRNA2, CHRNA6 NR1H2 208/4885CHRM2 24/4885CHRM1 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.